Article Information
History
- May 25, 2022.
Article Versions
- You are currently viewing Version 1 of this article (May 25, 2022 - 09:18).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Gabriele Romano1,2,#,
- Francesca Paradiso3,4,
- John P Miller5,
- Roger J Liang2,
- Jennifer A Wargo6,
- Francesca Taraballi3,
- James C Costello7 and
- Lawrence N Kwong2,#
- 1Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania
- 2Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas
- 3Center for Musculoskeletal Regeneration, Department of Orthopedics & Sports Medicine, Houston Methodist Research Institute, Houston, Texas
- 4Reproductive Biology and Gynaecological Oncology Group, Swansea University Medical School, Swansea, United Kingdom
- 5Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas
- 6Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
- 7Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado
- ↵#Correspondence to: Gabriele Romano, Drexel University, College of Medicine, Dept. of Pharmacology and Physiology, 245 North 15th Street, Philadelphia, PA 19102, gr476{at}drexel.edu, Lawrence Kwong, University of Texas MD Anderson Cancer Center, Department of Translational, Molecular Pathology, 2130 W Holcombe Blvd, Houston, TX 77030, LKwong{at}mdanderson.org
Posted May 25, 2022.
Microparticle-delivered Cxcl9 delays the relapse of Braf inhibitor-treated melanoma
